Steven Patrick Marso MD
Interventional Cardiology
Executive Medical Director CVSL, HCA Midwest Health
Join to view full profile
2330 E Meyer BlvdSte 509Kansas City, MO 64132
Phone+1 816-276-4800
Fax+1 816-523-1425
Dr. Marso is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Missouri-Kansas City School of MedicineFellowship, Interventional Cardiology, 1999 - 2000
Cleveland Clinic FoundationFellowship, Cardiovascular Disease, 1996 - 1999
University of Virginia Medical CenterResidency, Internal Medicine, 1993 - 1996
University of Kansas School of MedicineClass of 1993
Certifications & Licensure
KS State Medical License 2000 - 2026
MO State Medical License 1999 - 2024
TX State Medical License 2014 - 2018
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2016
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012, 2014-2016
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012-2013
Clinical Trials
Publications & Presentations
PubMed
- 113 citationsPaclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis: The AGENT IDE Randomized Clinical Trial.Robert W Yeh, Richard Shlofmitz, Jeffrey Moses, William Bachinsky, Suhail Dohad
JAMA. 2024-03-26 - 72 citationsEarly Utilization of Mechanical Circulatory Support in Acute Myocardial Infarction Complicated by Cardiogenic Shock: The National Cardiogenic Shock Initiative.Mir B Basir, Alejandro Lemor, Sarah Gorgis, Kirit C Patel, Brian C Kolski
Journal of the American Heart Association. 2023-12-05 - 75 citationsSemaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics.Ildiko Lingvay, Kirstine Brown-Frandsen, Helen M Colhoun, John Deanfield, Scott S Emerson
Obesity. 2023-01-01
Journal Articles
- Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER ExperienceSteven P Marso, John B Buse, Diabetes Care
Press Mentions
New Medical Director of Cardiovascular Services at HCA Midwest HealthNovember 7th, 2016
Semaglutide Reduces Stroke, Mortality in Patients with DiabetesSeptember 20th, 2016
SUSTAIN-6: Cardiovascular Safety of Semaglutide in Type 2 DiabetesSeptember 16th, 2016
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: